Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials

Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials

Abstract Introduction We conducted a post hoc analysis of efficacy and safety of filgotinib stratified by estimated radiographic progression rate before baseline (BL) in patients with rheumatoid arthritis (RA) who had inadequate response to methotrexate (MTX; FINCH 1; NCT02889796) or were naïve to i...

Full description

Bibliographic Details
Main Authors: Yoshiya Tanaka, Tatsuya Atsumi, Daniel Aletaha, Beatrix Bartok, Alena Pechonkina, Ling Han, Kahaku Emoto, Shungo Kano, Vijay Rajendran, Tsutomu Takeuchi
Format: Article
Language:English
Published: Adis, Springer Healthcare 2022-11-01
Series:Rheumatology and Therapy
Subjects:
Filgotinib
Adalimumab
Methotrexate
Rheumatoid arthritis
Online Access:https://doi.org/10.1007/s40744-022-00503-3

Internet

https://doi.org/10.1007/s40744-022-00503-3

Similar Items